Please ensure Javascript is enabled for purposes of website accessibility

What Investors Need to Know About Jazz Pharmaceuticals' Planned Acquisition of GW Pharmaceuticals

By Eric Volkman and Corinne Cardina - Feb 16, 2021 at 9:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Will the total be greater than the sum of the parts?

In the first marijuana industry buyout of 2021, Jazz Pharmaceuticals (JAZZ -0.67%) agreed to pay a hefty $7.6 billion to acquire GW Pharmaceuticals (GWPH), a developer of cannabis-based medications.

Will their fortunes suddenly change if the U.S. fully legalizes cannabis? Longtime Motley Fool contributor Eric Volkman and healthcare and cannabis bureau chief Corinne Cardina explore that possibility in this clip from Motley Fool Live recorded on Feb. 5, 2021.



Corinne Cardina: Another deal that was more recently announced just this week, Jazz Pharmaceuticals announced that they were going to be acquiring GW Pharmaceuticals. That is the British company that has the only FDA-approved CBD derived drug, Epidiolex.

Jazz may be a new name for pot investors. A lot of us not necessarily following smaller biotech pharmaceutical companies. Can you tell us about Jazz Pharmaceuticals and a little bit more about this deal?

Eric Volkman: Yeah. Like GW Pharmaceuticals, [Jazz] is based in Europe, they're based in Ireland. Originally established in California and they relocated., we can say, when there was a wave of that, particularly with pharmaceutical companies going to places like Ireland, which at the time had more favorable tax treatments.

Jazz, they're going to be facing a fairly tough time because their big seller is a narcolepsy drug called Xyrem. I could be pronouncing that wrong. X-Y-R-E-M, I think it's pronounced Xyrem. That forms the bulk of their revenue, which is great, except generics are coming. It's getting toward the end of its patent life. Generics are going to be coming by 2023, and that's tomorrow in terms of the pharmaceutical industry. It's coming very fast, in other words.

They need an asset or they need something that's going to anchor them for a little while -- a fairly unique drug that's not going to be under patent drug for a while. Epidiolex is perfect for that. It's the only medication approved in the U.S. that's based on cannabis substances. It was recently approved and because of that, it doesn't lose patent exclusivity until 2035, unless I'm greatly mistaken.

It's proven to be effective, it's getting more popular. 2020 sales last year: GW took in $510 million from it. That's up 72% year-on-year, which tells you something about the trajectory of that drug. Again, since it was recently approved, it's just getting started.

So, Jazz is looking at something like that and saying, "Oh, that'll be a nice thing to have in our portfolio." Again, unique, again, proven to be efficacious, proven to be effective, and on the way up. And it's got a long runway.

GW, that basically is their drug. They have another drug called Sativex which treats spasticity from multiple sclerosis. It's not as big as Epidiolex. Not least because it hasn't been approved in the U.S. yet. But that's the money drug for Jazz, and that's why they reached deep into their pockets to pay $7.2 million for that.

Corinne Cardina: $7.2 billion.

Eric Volkman: Billion. Yeah. I always get those confused. Those words are so common.

Corinne Cardina: They just matter a little bit. [laughs]

Eric Volkman: Yeah, exactly. Yeah, I stand corrected. But yeah, that $7.2 billion was around a 50% premium to GW's stock price the day before. That too tells you how critical this was for Jazz.

I think just for the wider marijuana sector, GW is a little bit of an outlier. It's unique because it's a pharmaceutical company, unlike pretty much every other weed stock. But just the fact that some formulation or use of cannabis substances are being taken seriously like that and have this value, I feel it's good for the overall sector.

Corinne Cardina: Yeah, that's a great point. What do you think about Jazz as a stock? Would you say that once this deal closes, do you think it's an attractive investment?

Eric Volkman: I don't know. I'm not crazy about pharmaceutical companies that are essentially one-trick ponies. I think Jazz needs more than Epidiolex. As good as it is, there's no argument that you can't make a case that Epidiolex is on the down. It certainly isn't.

But to me, if I were to invest in a pharmaceutical company with potential, I'd want maybe one other drug that has somewhat of a runway and somewhat of a market, and some kind of growth. Plus a decent pipeline. Jazz's pipeline doesn't seem very exciting to me. I don't know if I'd be an investor in Jazz.

I like GW as an independent company. As part of Jazz, I mean we'll see, but that combined company, I wouldn't be as hot on it as I would with GW if it was still stand-alone.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
$148.53 (-0.67%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.